Conditioning intensity in middle-aged patients with AML in first CR

No advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT

J. R. Passweg, M. Labopin, J. Cornelissen, L. Volin, G. Socié, A. Huynh, R. Tabrizi, D. Wu, C. Craddock, N. Schaap, J. Kuball, P. Chevallier, J. Y. Cahn, D. Blaise, A. Ghavamzadeh, K. Bilger, F. Ciceri, C. Schmid, S. Giebel, A. Nagler & 1 others M. Mohty

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

In recipients of allogeneic hematopoietic stem cell transplantation with AML in CR1, reduced intensity (RIC) conditioning regimens are usually given to older patients and myeloablative regimens (MAC) to younger patients. We analyzed whether in middle-aged patients aged 40-60 years, MAC was superior to RIC in cytogenetically higher risk AML. Among 2974 patients, 1638 had MAC and 1336 RIC transplants. Cytogenetics were high risk in 508, intermediate risk in 2297 and low risk in 169. Overall survival (OS) was higher in patients with RIC with low-risk cytogenetics but not in the intermediate- or poor-risk AML. Relapse incidence was lower with MAC in poor- and intermediate-risk AML. Nonrelapse mortality (NRM) was higher in MAC in all cytogenetic risk groups. Multivariate analysis confirmed a significant leukemia-free survival and OS advantage for RIC in low risk but no advantage of MAC in intermediate- and poor-risk leukemia. In patients aged 40-60 years, MAC has no advantage over RIC. We confirm lower relapse but higher NRM risks with MAC. MAC is not superior in patients with higher risk cytogenetics, but is inferior to RIC in the small cohort of AML patients with low-risk cytogenetics.

Original languageEnglish
Pages (from-to)1063-1068
Number of pages6
JournalBone Marrow Transplantation
Volume50
Issue number8
DOIs
Publication statusPublished - Aug 8 2015

Fingerprint

Leukemia
Cytogenetics
Survival
Recurrence
Mortality
Hematopoietic Stem Cell Transplantation
Multivariate Analysis
Transplants
Incidence

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Conditioning intensity in middle-aged patients with AML in first CR : No advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT. / Passweg, J. R.; Labopin, M.; Cornelissen, J.; Volin, L.; Socié, G.; Huynh, A.; Tabrizi, R.; Wu, D.; Craddock, C.; Schaap, N.; Kuball, J.; Chevallier, P.; Cahn, J. Y.; Blaise, D.; Ghavamzadeh, A.; Bilger, K.; Ciceri, F.; Schmid, C.; Giebel, S.; Nagler, A.; Mohty, M.

In: Bone Marrow Transplantation, Vol. 50, No. 8, 08.08.2015, p. 1063-1068.

Research output: Contribution to journalArticle

Passweg, JR, Labopin, M, Cornelissen, J, Volin, L, Socié, G, Huynh, A, Tabrizi, R, Wu, D, Craddock, C, Schaap, N, Kuball, J, Chevallier, P, Cahn, JY, Blaise, D, Ghavamzadeh, A, Bilger, K, Ciceri, F, Schmid, C, Giebel, S, Nagler, A & Mohty, M 2015, 'Conditioning intensity in middle-aged patients with AML in first CR: No advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT', Bone Marrow Transplantation, vol. 50, no. 8, pp. 1063-1068. https://doi.org/10.1038/bmt.2015.121
Passweg, J. R. ; Labopin, M. ; Cornelissen, J. ; Volin, L. ; Socié, G. ; Huynh, A. ; Tabrizi, R. ; Wu, D. ; Craddock, C. ; Schaap, N. ; Kuball, J. ; Chevallier, P. ; Cahn, J. Y. ; Blaise, D. ; Ghavamzadeh, A. ; Bilger, K. ; Ciceri, F. ; Schmid, C. ; Giebel, S. ; Nagler, A. ; Mohty, M. / Conditioning intensity in middle-aged patients with AML in first CR : No advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT. In: Bone Marrow Transplantation. 2015 ; Vol. 50, No. 8. pp. 1063-1068.
@article{757a9b0723a648639a1d94b15a26b3db,
title = "Conditioning intensity in middle-aged patients with AML in first CR: No advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT",
abstract = "In recipients of allogeneic hematopoietic stem cell transplantation with AML in CR1, reduced intensity (RIC) conditioning regimens are usually given to older patients and myeloablative regimens (MAC) to younger patients. We analyzed whether in middle-aged patients aged 40-60 years, MAC was superior to RIC in cytogenetically higher risk AML. Among 2974 patients, 1638 had MAC and 1336 RIC transplants. Cytogenetics were high risk in 508, intermediate risk in 2297 and low risk in 169. Overall survival (OS) was higher in patients with RIC with low-risk cytogenetics but not in the intermediate- or poor-risk AML. Relapse incidence was lower with MAC in poor- and intermediate-risk AML. Nonrelapse mortality (NRM) was higher in MAC in all cytogenetic risk groups. Multivariate analysis confirmed a significant leukemia-free survival and OS advantage for RIC in low risk but no advantage of MAC in intermediate- and poor-risk leukemia. In patients aged 40-60 years, MAC has no advantage over RIC. We confirm lower relapse but higher NRM risks with MAC. MAC is not superior in patients with higher risk cytogenetics, but is inferior to RIC in the small cohort of AML patients with low-risk cytogenetics.",
author = "Passweg, {J. R.} and M. Labopin and J. Cornelissen and L. Volin and G. Soci{\'e} and A. Huynh and R. Tabrizi and D. Wu and C. Craddock and N. Schaap and J. Kuball and P. Chevallier and Cahn, {J. Y.} and D. Blaise and A. Ghavamzadeh and K. Bilger and F. Ciceri and C. Schmid and S. Giebel and A. Nagler and M. Mohty",
year = "2015",
month = "8",
day = "8",
doi = "10.1038/bmt.2015.121",
language = "English",
volume = "50",
pages = "1063--1068",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Conditioning intensity in middle-aged patients with AML in first CR

T2 - No advantage for myeloablative regimens irrespective of the risk group-an observational analysis by the Acute Leukemia Working Party of the EBMT

AU - Passweg, J. R.

AU - Labopin, M.

AU - Cornelissen, J.

AU - Volin, L.

AU - Socié, G.

AU - Huynh, A.

AU - Tabrizi, R.

AU - Wu, D.

AU - Craddock, C.

AU - Schaap, N.

AU - Kuball, J.

AU - Chevallier, P.

AU - Cahn, J. Y.

AU - Blaise, D.

AU - Ghavamzadeh, A.

AU - Bilger, K.

AU - Ciceri, F.

AU - Schmid, C.

AU - Giebel, S.

AU - Nagler, A.

AU - Mohty, M.

PY - 2015/8/8

Y1 - 2015/8/8

N2 - In recipients of allogeneic hematopoietic stem cell transplantation with AML in CR1, reduced intensity (RIC) conditioning regimens are usually given to older patients and myeloablative regimens (MAC) to younger patients. We analyzed whether in middle-aged patients aged 40-60 years, MAC was superior to RIC in cytogenetically higher risk AML. Among 2974 patients, 1638 had MAC and 1336 RIC transplants. Cytogenetics were high risk in 508, intermediate risk in 2297 and low risk in 169. Overall survival (OS) was higher in patients with RIC with low-risk cytogenetics but not in the intermediate- or poor-risk AML. Relapse incidence was lower with MAC in poor- and intermediate-risk AML. Nonrelapse mortality (NRM) was higher in MAC in all cytogenetic risk groups. Multivariate analysis confirmed a significant leukemia-free survival and OS advantage for RIC in low risk but no advantage of MAC in intermediate- and poor-risk leukemia. In patients aged 40-60 years, MAC has no advantage over RIC. We confirm lower relapse but higher NRM risks with MAC. MAC is not superior in patients with higher risk cytogenetics, but is inferior to RIC in the small cohort of AML patients with low-risk cytogenetics.

AB - In recipients of allogeneic hematopoietic stem cell transplantation with AML in CR1, reduced intensity (RIC) conditioning regimens are usually given to older patients and myeloablative regimens (MAC) to younger patients. We analyzed whether in middle-aged patients aged 40-60 years, MAC was superior to RIC in cytogenetically higher risk AML. Among 2974 patients, 1638 had MAC and 1336 RIC transplants. Cytogenetics were high risk in 508, intermediate risk in 2297 and low risk in 169. Overall survival (OS) was higher in patients with RIC with low-risk cytogenetics but not in the intermediate- or poor-risk AML. Relapse incidence was lower with MAC in poor- and intermediate-risk AML. Nonrelapse mortality (NRM) was higher in MAC in all cytogenetic risk groups. Multivariate analysis confirmed a significant leukemia-free survival and OS advantage for RIC in low risk but no advantage of MAC in intermediate- and poor-risk leukemia. In patients aged 40-60 years, MAC has no advantage over RIC. We confirm lower relapse but higher NRM risks with MAC. MAC is not superior in patients with higher risk cytogenetics, but is inferior to RIC in the small cohort of AML patients with low-risk cytogenetics.

UR - http://www.scopus.com/inward/record.url?scp=84938955303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84938955303&partnerID=8YFLogxK

U2 - 10.1038/bmt.2015.121

DO - 10.1038/bmt.2015.121

M3 - Article

VL - 50

SP - 1063

EP - 1068

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 8

ER -